Akèy › Kansè lestomak › Nebraska › Omaha
Etid klinik pou Kansè lestomak nan Omaha, NE
9 etid pou Kansè lestomak ap chèche patisipan nan sit nan ak bò kote Omaha (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Ap rekriteVolontè an sante akeyi
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Ap rekriteFaz 2/3
- Local Institution - 0286, Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Ap rekriteFaz 1/2
- Nebraska Cancer Specialists, Omaha
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Ap rekriteFaz 1/2
- Nebraska Cancer Specialists, Omaha
Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- ak 1 plis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Ap rekriteFaz 3
- Nebraska Cancer Specialists, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Omaha
Etid Kansè lestomak nan lòt vil
- Houston, TX42 etid
- Boston, MA32 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA22 etid
- Baldwin Park, CA22 etid
- Arlington, VA20 etid
- Dallas, TX19 etid
- San Antonio, TX19 etid
- Grand Rapids, MI18 etid
- St. Louis, MO18 etid
- Washington, DC16 etid
Lòt etid nan Omaha
- Kansè pwostat27 etid
- Kansè Poumon ki pa ti selil24 etid
- Kansè nan tete22 etid
- Kansè kolorektal18 etid
- Kansè (tout kalite)18 etid
- Myelom Miltip16 etid
- Limfòm Non-Hodgkin14 etid
- Kansè ovè14 etid
- Kansè pankreyas14 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
- Ensifizyans kadyak13 etid
- Kansè Metastatik13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.